Medical News Hour

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ:APCVZ) announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market Chlorothiazide Sodium for Injection, USP. APP expects to launch Chlorothiazide Sodium for Injection, USP in the fourth quarter of 2009.

See more here:

APP Pharmaceuticals Receives Approval For The First Generic Chlorothiazide Sodium For Injection, USP

Related posts:

1. APP Pharmaceuticals Receives Approval For Deferoxamine Mesylate For Injection, USP
2. Teva Receives Final Approval For Generic Prevacid(R) Delayed-Release Capsules
3. Reverse Medical Corporation Receives FDA IDE Clinical Study Approval For The ReStoreTM Microcatheter
4. Mylan’s Matrix Receives Tentative FDA Approval Under PEPFAR For Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate Tablets
5. Novartis Receives Approval In The European Union For Onbrez® Breezhaler®, A New Once-daily Bronchodilator For Patients With COPD